Winds of change: 
China’s Biopharma Innovation 2.0 Era

Winds of change: China ’s Biopharma Innovation 2.0 Era

A landmark insight from Clarivate.
 

Mainland China is now the second-largest market for new drug launches, driving global biopharma transformation. Our latest report, China Biopharma Innovation 2.0, reveals how supportive policies, cutting-edge technologies, and strategic partnerships are shaping the future of healthcare.

18%

of global first launches of NMEs

450%

growth in patents since 2020

$50B

in out-licensing deals

38%

share of global TPD publications

Access the full Clarivate report now

 Download report
 

This report includes:

  • Historic milestone: 18% of global first launches of NMEs in 2024.
  • $50B out-licensing surge: Record-breaking deals signal global confidence.
  • Emerging tech ceadership: 38% of global TPD publications and 37% of patents.
  • Top 100 Innovators: 450% growth in patents and 110% increase in clinical trials since 2020.
 

“China’s biopharma innovation landscape has evolved from rapid expansion to sustainable, quality-focused development — a true sign of maturity.”

— Michael Ward,
Industry Thought Leader, Head of Life Sciences & Healthcare, Clarivate
Special thanks

Hozana Castillo

Manager Solution Consulting team, Asia-Pacific Region
In partnership

Pharma Manager

Exclusive Strategic Partner of China’s Top 100 Pharmaceutical Innovation Enterprises

Discover how Mainland China evolved from rapid growth to quality-driven development, becoming a global leader in pharmaceutical innovation.

 Download report


From China to the world

As the industry continues to evolve, Clarivate will keep publishing insights on China’s life sciences market and thought leadership content on international expansion.

2024 Report

A decade of innovation, a decade to come

Driven by ambitious policies, R&D investments, and a reformed regulatory landscape—including initiatives like Made in China 2025 and Healthy China 2030—China now contributes 23% of the global innovative drug pipeline. Our 2024 report explores how strategic hubs, streamlined approvals, and next-generation research are shaping the future of healthcare accessibility and affordability.

Read the 2024 report

 

Access the full report

Complete the form below to download your copy.

HIDDEN FIELDS BELOW